Specify a stock or a cryptocurrency in the search bar to get a summary
Vivani Medical Inc.
VANIVivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California. Address: 1350 South Loop Road, Alameda, CA, United States, 94502
Analytics
WallStreet Target Price
5.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures VANI
Dividend Analytics VANI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History VANI
Stock Valuation VANI
Financials VANI
Results | 2019 | Dynamics |